Release Date: 20-Aug-2014
“COPD Drug Market Opportunity & Clinical Pipeline Analysis” Report Highlight:
Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli.
Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler. The global market for COPD has been estimated to be close to US$ 12 billion in 2013 & would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018.
For Report Sample Visit Report Weblink: “COPD Drug Market Opportunity & Clinical Pipeline Analysis”
Or Contact: email@example.com